Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.34 |
| ▸ | GRN | P28799 | 1/20 | 0.33 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL610149 | 0.81 | GRN (0.33) | GRNSORT1 | |
| SCHEMBL16330912 | 0.81 | GRN (0.33) | GRNSORT1 | |
| SCHEMBL13736040 | 0.81 | GRN (0.33) | GRNSORT1 | |
| SCHEMBL15152152 | 0.79 | — | — | |
| SCHEMBL4985742 | 0.78 | — | — | |
| SCHEMBL1863350 | 0.78 | GRN (0.32) | GRNSORT1 | |
| SCHEMBL1863348 | 0.78 | GRN (0.32) | GRNSORT1 | |
| SCHEMBL20480001 | 0.78 | CYP2D6 (0.45) | GRNSORT1 | |
| SCHEMBL16094266 | 0.76 | — | — | |
| Trifluoroacetic Acid SCHEMBL15664323 | 0.75 | ESR1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3389654-B1 | DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20180362518-A1 | DIAMINO-ALKYLAMINO-Linked ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2018-12-20 | — | — | US | disclosed |
| US-9579320-B2 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150297595-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. | 2015-10-22 | — | — | US | disclosed |
| EP-2323993-B1 | 2,6-DIAMINO- PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS | PORTOLA PHARM INC (US) | 2015-06-03 | — | — | EP | disclosed |
| US-8952027-B2 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-8859548-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG (CH) | 2014-10-14 | — | — | US | disclosed |
| EP-2470528-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-10-01 | — | — | EP | disclosed |
| US-20140011825-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS AG (CH) | 2014-01-09 | — | — | US | disclosed |
| US-20120225899-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-09-06 | — | — | US | disclosed |
| US-8242260-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG (CH) | 2012-08-14 | — | — | US | disclosed |
| US-20120130073-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8063058-B2 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20110052578-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-03-03 | — | — | US | disclosed |
| EP-2274300-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | Novartis AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-20100048567-A1 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| WO-2009115572-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | NOVARTIS AG (CH) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297595-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | SYK, BTK, JAK1 | DNM1 3674/4885GRN 3941/4885SORT1 1919/4885 |
| US-20180362518-A1 | DIAMINO-ALKYLAMINO-Linked ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | TRPV1, SCN7A, SCN1A | DNM1 2233/4885GRN 4003/4885SORT1 2750/4885 |
| US-20110052578-A1 | Compounds and Compositions as Protein Kinase Inhibitors | RAF1, BRAF, ARAF | DNM1 3960/4885GRN 2690/4885SORT1 3968/4885 |
| US-20120130073-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | SYK, BTK, JAK1 | DNM1 3674/4885GRN 3941/4885SORT1 1919/4885 |
| US-20120225899-A1 | Compounds and Compositions as Protein Kinase Inhibitors | RAF1, BRAF, ARAF | DNM1 3960/4885GRN 2690/4885SORT1 3968/4885 |
| US-20100048567-A1 | Inhibitors of syk and JAK protein kinases | SYK, BTK, JAK1 | DNM1 3674/4885GRN 3941/4885SORT1 1919/4885 |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | DNM1 3392/4885GRN 2387/4885SORT1 4578/4885 |
| US-20140011825-A1 | Compounds and Compositions as Protein Kinase Inhibitors | RAF1, BRAF, ARAF | DNM1 3960/4885GRN 2690/4885SORT1 3968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.